Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Revenue of Sanofi's pharmaceutical segment by product group from 2015 to 2018
(in million euros)
Sanofi - pharmaceutical segment revenues by product group 2015-2018
This statistic shows the revenue of Sanofi's pharmaceutical segment by product groups from 2015 to 2018. In 2018, Sanofi's pharmaceutical group generated 1.49 billion euros in revenue oncology products. Sanofi is one of the top global pharmaceutical companies. It is headquartered in Paris, France.

Sanofi's segments

Sanofi’s pharmaceutical segment generated 5.5 billion euros in revenue through its diabetes product group in 2018, a decrease compared to 7.6 billion euros in 2015. Lantus is one of Sanofi’s best selling pharmaceutical products. Its revenue has risen from 2.4 billion euros in 2008 to 6.39 billion euros in 2015, but decreased to 3.6 billion in 2018. Lantus is an insulin glargine used daily to control blood sugar levels of patients with diabetes. Clopidogrel, which is marketed under Sanofi’s trade name Plavix, generated 1.44 billion euros in 2018. Plavix is an oral agent that prevents blood clots in patients with some types of heart disease and also prevents heart attacks.

Among its vaccination segment, Sanofi has several profitable products. The company’s influenza vaccines generated over 1.7 billion euros in 2018. Fluzone is a marketed brand of Sanofi’s influenza vaccine, of which varieties exist to target persons of certain age groups.

Sanofi originated in 1973 as a subsidiary of Elf Aquitaine, the company ventured into the U.S. market in 1994. Although, the company is primarily focused on the pharmaceutical market, it also maintains an animal health segment. This segment develops products in four groups including antiparasitics and antiinfectives. Sanofi generated some 34.5 billion euros in total revenues in 2018. The company expended approximately 5.9 billion euros the same year on research and development ventures.
Revenue of Sanofi's pharmaceutical segment by product group from 2015 to 2018
(in million euros)
2015201620172018
-----
-----
-----
-----
-----
-----
-----
-----
-----
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

March 2019

Region

Worldwide

Survey time period

2015 to 2018

Sanofi - pharmaceutical segment revenues by product group 2015-2018
This statistic shows the revenue of Sanofi's pharmaceutical segment by product groups from 2015 to 2018. In 2018, Sanofi's pharmaceutical group generated 1.49 billion euros in revenue oncology products. Sanofi is one of the top global pharmaceutical companies. It is headquartered in Paris, France.

Sanofi's segments

Sanofi’s pharmaceutical segment generated 5.5 billion euros in revenue through its diabetes product group in 2018, a decrease compared to 7.6 billion euros in 2015. Lantus is one of Sanofi’s best selling pharmaceutical products. Its revenue has risen from 2.4 billion euros in 2008 to 6.39 billion euros in 2015, but decreased to 3.6 billion in 2018. Lantus is an insulin glargine used daily to control blood sugar levels of patients with diabetes. Clopidogrel, which is marketed under Sanofi’s trade name Plavix, generated 1.44 billion euros in 2018. Plavix is an oral agent that prevents blood clots in patients with some types of heart disease and also prevents heart attacks.

Among its vaccination segment, Sanofi has several profitable products. The company’s influenza vaccines generated over 1.7 billion euros in 2018. Fluzone is a marketed brand of Sanofi’s influenza vaccine, of which varieties exist to target persons of certain age groups.

Sanofi originated in 1973 as a subsidiary of Elf Aquitaine, the company ventured into the U.S. market in 1994. Although, the company is primarily focused on the pharmaceutical market, it also maintains an animal health segment. This segment develops products in four groups including antiparasitics and antiinfectives. Sanofi generated some 34.5 billion euros in total revenues in 2018. The company expended approximately 5.9 billion euros the same year on research and development ventures.
Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Statistics on "Sanofi"
  • Global positioning
  • Overview
  • Revenue distribution
  • Company shares
Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.